Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Inmune Bio, Inc. (INMB)
|
Add to portfolio |
|
|
|
| Price: |
$10.11
| | Metrics |
| OS: |
18.0
|
M
| |
-53
|
% ROE
|
| Market cap: |
$182
|
M
| |
-122
|
% ROIC
|
|
Net cash:
|
$33
|
M
| |
$1.83
|
per share
|
|
EV:
|
$149
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($25.9)
|
M
| |
|
|
|
EBIT
|
($25.9)
|
M
| |
|
|
| EPS |
($1.48)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.4 | 0.2 | 0.0 | 9.3 | 0.0 | 0.0 |
| Revenue growth | 106.6% | 1545.5% | -99.9% | | | |
| Cost of goods sold | 0.0 | -30.5 | -13.1 | 0.0 | 0.0 | -1.1 |
| Gross profit | 0.4 | 30.7 | 13.1 | 9.3 | 0.0 | 1.1 |
| Gross margin | 100.0% | 16961.3% | 119281.8% | 100.0% | | |
| Research and development | 17.1 | 20.5 | 5.9 | 3.3 | 3.4 | 0.4 |
| General and administrative | 9.3 | 8.8 | 6.3 | 6.0 | 9.1 | 0.5 |
| EBIT | -25.9 | -26.8 | -11.5 | -7.8 | -12.4 | -0.8 |
| EBIT margin | -6934.0% | -14796.1% | -104418.2% | -83.4% | | |
| Pre-tax income | -27.3 | -30.3 | -12.1 | -7.7 | -12.4 | -0.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -27.3 | -30.3 | -12.1 | -7.7 | -12.4 | -0.8 |
| Net margin | -7299.2% | -16762.4% | -109990.9% | -82.6% | | |
| |
| Diluted EPS | ($1.52) | ($1.88) | ($1.01) | ($0.75) | ($1.43) | ($0.13) |
| Shares outstanding (diluted) | 17.9 | 16.1 | 12.0 | 10.3 | 8.7 | 6.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|